247 related articles for article (PubMed ID: 37895145)
21. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model.
Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q
Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model.
Jia Y; Yin Y; Duan F; Fu H; Hu M; Gao Y; Pan Z; Jiao X
Int J Mol Med; 2012 Dec; 30(6):1335-42. PubMed ID: 23027427
[TBL] [Abstract][Full Text] [Related]
23. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
24. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Seo SH; Jin HT; Park SH; Youn JI; Sung YC
Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
[TBL] [Abstract][Full Text] [Related]
25. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
Bahrami AA; Ghaemi A; Tabarraei A; Sajadian A; Gorji A; Soleimanjahi H
J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
[TBL] [Abstract][Full Text] [Related]
26. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
[TBL] [Abstract][Full Text] [Related]
27. A Genetically Modified attenuated
Jia YY; Tan WJ; Duan FF; Pan ZM; Chen X; Yin YL; Jiao XA
Front Cell Infect Microbiol; 2017; 7():279. PubMed ID: 28706878
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus 16 E6/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p/PD-L1 axis.
Ling J; Sun Q; Tian Q; Shi H; Yang H; Ren J
Arch Biochem Biophys; 2022 Nov; 731():109449. PubMed ID: 36288761
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome-Positive C3 Cancers in Mice.
Boilesen DR; Neckermann P; Willert T; Müller MD; Schrödel S; Pertl C; Thirion C; Asbach B; Wagner R; Holst PJ
Cancer Immunol Res; 2023 Feb; 11(2):261-275. PubMed ID: 36534088
[TBL] [Abstract][Full Text] [Related]
30. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
31. Immunization of mice by the co-administration of codon-optimized HPV16 E7 and lL12 genes against HPV16-associated cervical cancer.
Ajorloo M; Alamdary A; Soleimanjahi H; El Boulani A; Khanizadeh S; Nikoo HR
Microb Pathog; 2019 Jul; 132():20-25. PubMed ID: 31004722
[TBL] [Abstract][Full Text] [Related]
32. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
33. A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model.
Qi W; Qingfeng L; Jing Z; Maolin Z; Zhihui Z; Wangqi D; Shanli Z; Jun C; Pengfei J; Lifang Z
Vaccine; 2022 Dec; 40(52):7693-7702. PubMed ID: 36376215
[TBL] [Abstract][Full Text] [Related]
34. Combination Vaccination With Tetanus Toxoid and Enhanced Tumor-Cell Based Vaccine Against Cervical Cancer in a Mouse Model.
Alson D; Schuyler SC; Yan BX; Samimuthu K; Qiu JT
Front Immunol; 2020; 11():927. PubMed ID: 32547541
[TBL] [Abstract][Full Text] [Related]
35. Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells.
Wu XM; Liu X; Jiao QF; Fu SY; Bu YQ; Song FZ; Yi FP
Asian Pac J Cancer Prev; 2014; 15(6):2447-51. PubMed ID: 24761845
[TBL] [Abstract][Full Text] [Related]
36. Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector.
Peng S; Tu H-F; Cheng M; Hu M-H; Tsai H-L; Tsai Y-C; Koenig C; Brayton C; Wang H; Chang Y-N; Arend RC; Levinson K; Roden RBS; Wu TC; Hung C-F
mBio; 2023 Oct; 14(5):e0212123. PubMed ID: 37791765
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
38. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model.
Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M
Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991
[TBL] [Abstract][Full Text] [Related]
39. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.
Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670
[TBL] [Abstract][Full Text] [Related]
40. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
